China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical service agreement with compatriot firm Happy Life Tech (HLT), an affiliate of Yidu Tech (HKG: 2158). The agreement focuses on recombinant human nerve growth factor eye drops, targeting moderate to severe dry eye conditions.
Phase III Study Details
Under the terms of the agreement, a multi-center, randomized, double-blinded, placebo-controlled Phase III study will be conducted to assess the efficacy and safety of the recombinant human nerve growth factor eye drops. Happy Life Tech will provide comprehensive clinical trial technical services to support the study.
Intellectual Property Rights
All intellectual properties generated through the clinical trial process will belong to Sinobioway, ensuring that the company retains full rights to any innovations and data resulting from the study. Financial details of the agreement have not been disclosed.-Fineline Info & Tech
